Drugs News and Research

RSS

CVD/MI complications tend to occur within first 30 days after PCI

Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a balloon-tipped tube into the vessel. Sometimes a stent is also inserted to keep the blood vessel open.

26 Mar 2012

S. gordonii may trigger infective endocarditis

Oral bacteria that escape into the bloodstream are able to cause blood clots and trigger life-threatening endocarditis. Further research could lead to new drugs to tackle infective heart disease, say scientists presenting their work at the Society for General Microbiology's Spring Conference in Dublin this week.

26 Mar 2012

Metformin can have protective effects on the heart

The widely used diabetes medicine metformin can have protective effects on the heart, reveals a new study conducted at the Sahlgrenska Academy, at the University of Gothenburg, Sweden.

26 Mar 2012

Positive results from Amgen's AMG 145 Phase 1b study on patients with LDL-C

Amgen announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as "bad" cholesterol, by up to 81 percent versus placebo (maximum reduction) in subjects on low to moderate doses of statins/

26 Mar 2012

New method for measurement of aggregated beta-amyloid in AD

An international team of researchers have developed a new method for measurement of aggregated beta-amyloid - a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease. The new method might facilitate diagnosis and detection as well as development of drugs directed against aggregated beta-amyloid.

26 Mar 2012

Islet Sciences acquires DTI

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes which is now the Company's wholly owned subsidiary.

26 Mar 2012

FDA Advisory Committee to review Repligen's SecreFlo NDA on May 31

Repligen Corporation today announced that the U.S. Food and Drug Administration's Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the Company's New Drug Application (NDA) for SecreFlo for the improved detection of pancreatic duct abnormalities in combination with magnetic resonance imaging (MRI) in patients with pancreatitis.

26 Mar 2012

Dissolvable tobacco harmless finds FDA panel but promises detailed review

An advisory panel to the Food and Drugs Administration (FDA) said Thursday that people who exclusively use dissolvable tobacco products have a greatly reduced risk of cancer and respiratory illness compared with those who regularly smoke cigarettes.

25 Mar 2012

Heart attack may soon be predicted by a simple blood test

Researchers have found a simple test that could predict whether a patient is about to have a heart attack. They used a blood sample to detect cells that have sloughed off of damaged blood vessel walls to predict a heart attack.

25 Mar 2012

New cholesterol lowering drugs on the horizon

The new drugs in development by pharmaceutical makers are injectable medications that block a protein called PCSK9. These drugs have shown promise in early clinical trials for slashing bad LDL cholesterol further than widely used statins can alone. Their biggest advocates say PCSK9 blockers have the potential to be the next multibillion-dollar class of heart drugs.

25 Mar 2012

Male pattern baldness causes discovered

Most men start to go bald in middle age, with about 80% of men having some hair loss by the age of 70. Male pattern baldness is the most common type of hair loss for men, the National Institute of Health said. Symptoms include a thinning of hair at the hairline, eventually creating a U-shaped or horseshoe pattern of hair on both sides of the head. The male sex hormone testosterone plays a key role, as do genetic factors. They cause the hair follicles to shrink, eventually becoming so small that they are invisible, leading to the appearance of baldness. While treatment is not necessary, side effects including psychological stress and loss of self-esteem due to change in appearance can be experienced.

25 Mar 2012

Lawmakers examine how Medicare, Medicaid can help stop prescription painkiller abuse

Lawmakers held a hearing Thursday on what steps the federal government can take to help prevent the abuse of prescription painkillers.

23 Mar 2012

Aternative pain medication without narcotics safe after sinus surgery

Patients who have undergone sinus surgery can safely take an alternative pain medication that does not cause the side effects of narcotics such as fentanyl and Vicodin, a Loyola University Health System study has found.

23 Mar 2012

Africa must develop its own pharmaceutical pipeline through creation of policy frameworks

"To break free of its dependence on donor money and supplies from India, Africa must develop its own pharmaceutical pipeline by creating policy frameworks that encourage a fledgling drug industry," journalist Priya Shetty argues in this SciDev.Net opinion piece.

23 Mar 2012

Fraunhofer FIT software rapidly analyzes complex biological processes

At Analytica 2012, Fraunhofer FIT presents software that supports the search for new active pharmaceutical ingredients of cancer drugs. Through a high degree of parallelization, the software can analyze complex biological processes very fast, even with large amounts of data.

23 Mar 2012

Deficiency of Mitofusin 2 protein leads to insulin resistance, glucose intolerance

The study shows that the lack of Mitofusin 2 in mice produces insulin resistance and glucose intolerance, the main causes of diabetes.

23 Mar 2012

Lancet editorial calls for TB control, elimination efforts to be on G20 agenda

In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."

23 Mar 2012

Combination of everolimus and exemestane reduces spread of cancer in the bone

Results from a phase III clinical trial evaluating a new treatment for breast cancer in post-menopausal women show that the combination of two cancer drugs, everolimus and exemestane, significantly improves bone strength and reduces the chances of cancer spreading (metastasising) in the bone.

23 Mar 2012

Viewpoints: Ryan budget not a balanced diet; DEA war on pharmacies; The debate over Medicaid block grants

The mother of all tax expenditures - the tax-free treatment of employer-sponsored health insurance - amounts to $2 trillion over 10 years in lost income-tax revenue, not including the additional impact on payroll tax collections.

23 Mar 2012

Genetic marker identifies tumors unable to repair DNA damage by platinum agents

Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

23 Mar 2012